Friday, November 13, 2026

Healthcare Corporate Finance

1 article

Intuitive Surgical Wins Da Vinci 5 Approvals in Europe and Japan, Q4 Earnings Beat Estimates

Intuitive Surgical secured regulatory clearances for its da Vinci 5 surgical system in Europe and Japan following a Q4 earnings beat, opening two major markets for its next-generation robotic platform. The approvals position the company for accelerated international revenue growth as healthcare systems deploy capital on advanced surgical equipment. Strong placement activity signals sustained institutional demand for robotic surgery infrastructure.

ViaNews Editorial Team (Finance)•Feb 26, 2026

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic

Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

Ford Motor Company

Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,995

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,995 facts checked against source5,577 source documents archived

Query this data → isubstrate.com